Objective: To characterize reverse transcriptase (RT) mutations by their association with extent of nucleoside RT inhibitor (NRTI) therapy. To identify mutational clusters in RT sequences from persons receiving multiple NRTI.
Introduction
Sequencing of HIV-1 reverse transcriptase (RT) and protease is recommended to help select optimal antiretroviral therapy [1] [2] [3] [4] . Mutations at 18 RT residues have been shown experimentally to reduce HIV-1 susceptibility to nucleoside RT inhibitors (NRTI) [1, 5] . However, many other RT mutations are typically found during sequencing of clinical isolates and the effect of these other mutations on drug susceptibility is not known. Some of these may be neutral polymorphisms; others may contribute to drug resistance.
We analyzed RT sequences from more than 1100 individuals -including nearly 500 previously unreported sequences -to characterize RT mutations according to their association with NRTI or nonnucleoside RT inhibitors (NNRTI), to identify mutations that increased in proportion to the extent of NRTI therapy, and to identify statistically significant correlations between known drug resistance mutations and previously unreported drug-associated mutations.
Methods

Isolates and sequences
We analyzed HIV-1 RT sequences from individuals having both subtype B viruses and well-characterized antiretroviral treatment histories. We obtained these sequences from previously published studies (appearing in the April 15, 2002 release of the Stanford University HIV RT and Protease Sequence Database; http:// hivdb.stanford.edu [6] ) and from sequences performed at the Stanford University Hospital Diagnostic Virology Laboratory between 1 July 1997 and 31 December 2001 (see Appendix for GenBank accession numbers). Isolates were subtyped by comparing their sequences with reference sequences of known subtype [7, 8] and by bootscanning using a window size of 200 base pairs (bp) and steps of 20 bp [9] .
The treatment histories of individuals described in the literature were obtained from the primary publication and were often supplemented by clarifications obtained directly from the authors. The treatment histories of individuals undergoing sequencing at Stanford were obtained by reviewing their medical records. Isolates from individuals lacking a complete record of which NRTI and NNRTI had been received were excluded from analysis.
When an individual had multiple isolates, we included the most recent isolate obtained while the individual was receiving an RT inhibitor. We included more than one isolate from the same individual only when isolates were available both before and after beginning initial treatment with an RT inhibitor, in which case we included one pre-treatment isolate and the most recent post-treatment isolate. Only isolates that included positions 40-240 and that were sequenced by dideoxynucleotide sequencing (i.e., not by hybridization assays) were included in the analysis.
Mutations
Mutations were defined as differences from the consensus B sequence [7] . Sequences having a mixture of wild-type (consensus B sequence) and mutant residues at a single position were considered to have a mutation at that position. Mixtures were detected by clonal sequencing if at least two clones contained the same non-consensus residue. Mixtures were detected by direct PCR sequencing if a non-consensus residue was represented by an electrophoretic peak at least 20-30% of the largest peak present. [1] . Positions with fewer than five mutations were considered invariant.
Statistical analysis
To identify positions associated with drug therapy, we performed chi-square tests of independence to determine if there was an association between drug treatment and a mutation at the given position. The chi-square statistic was based on a 2 3 2 contingency table containing counts of individuals with and without NRTI treatment and those with and without mutations at the given position. For most positions, we performed the analysis on the NNRTI-naive subset of patients who had not received any NNRTI therapy. For selected positions, when the number of observed mutations in this subset was too small or when we wished to study a mutation previously reported in the literature, we extended the chi-square analysis to include the total set of patients.
To investigate whether there was a linear relationship between the number of NRTI received and the prevalence of a mutation, we performed a logistic regression analysis in which the number of drugs was the independent variable and the presence or absence of mutation was the dependent variable. Patients were categorized into one of three groups according to extent of treatment: light (one to two NRTI), medium (three to four NRTI), and heavy (five or more NRTI). As with the chi-square analysis, we performed the analysis on the NNRTI-naive subset of patients, but extended the analysis to the total set of patients for selected positions. our analysis for NRTI therapy. We included all patients in this analysis. We did not perform a logistic regression analysis in this case to study linear relationships, because most patients received at most one NNRTI.
For all of the above tests, we determined which results were statistically significant by applying the method of Benjamini and Hochberg [10] . This method was developed for the problem of multiple hypotheses testing when multiple significant findings are not unexpected. In contrast to the Bonferroni correction, which divides the significance cutoff by the number of hypotheses tested (n), the Benjamini-Hochberg method ranks the hypothesis by their P values. Each hypothesis of rank r is compared with a significance cutoff, now called a false discovery rate (FDR), divided by (nÀr). In this study, FDR of 0.01 and 0.05 were used to determine statistical significance.
We investigated the correlation of mutations between positions induced by NRTI and NNRTI therapy, by calculating the binomial (phi) correlation coefficient for the simultaneous presence of mutations at two positions in the same isolate. We computed the correlations for the subset of patients who had received three or more NRTI and for the subset of individuals that had received an NNRTI. We further investigated the relationships among positions by performing a principal components analysis on the patients who had received three or more NRTI. We used the matrix of correlation coefficients as a measure of similarity between positions. All statistical analysis was performed using the statistical programming package Splus. Table 1 groups the individuals in the study according to their treatment histories. Sequences of 1210 isolates from 1124 individuals met our study criteria. Eightysix individuals had sequences of two isolates each, including one pre-therapy and one post-therapy isolate. Sequences of 569 (47.0%) isolates had been previously published; sequences of 641 (53.0%) isolates were performed at Stanford University Hospital between 1 July 1997 and 31 December 2001. 267 (22.1%) isolates were from previously untreated individuals; 584 (48.2%) isolates were from individuals receiving NRTI but not NNRTI; 357 (29.5%) isolates were from individuals who received both NRTI and NNRTI; two (0.2%) isolates were from individuals who received NNRTI but not NRTI.
Results
Treatment histories
Number of RT mutations and extent of previous NRTI treatment Fig. 1 shows the median number of differences from consensus B (mutations) and known drug resistance mutations per sequence as a function of the number of NRTI received. The figure shows that the number of mutations increases from four in untreated individuals to 14 in individuals receiving five or more NRTI, while the median number of known NRTI resistance mutations increased from zero in untreated individuals to six in individuals receiving five or more NRTI. The median number of known NNRTI resistance mutations increased from zero in untreated individuals to one in individuals receiving one or more NNRTI. There was a statistically significant stepwise increase in the number of mutations and NRTI resistance mutations associated with increasing NRTI exposure. This relationship was observed in the NNRTI-naive subset as well as the total set of individuals. 0  0  0  0  0  0  0  0  0  267  2  46  223  1  1  0  0  54  5  0  15  0  73  2  19  56  2  138  1  1  189  113  17  135  0  269  28  132  165  3  119  4  2  115  84  31  47  0  87  47  94  40  4  221  24  5  218  213  52  175  0  96  131  177  50  5+  206  93  43  206  207  146  204  0  59  149  173  35  Total:  685  122  51  782  622  246  576  0  851  359  641  569   a The table shows have not been known to be associated with NRTI resistance (20, 39, 43, 203, 208, 218 , and 228).
RT mutations and NRTI treatment
Extension of our chi-square analysis to the total set of patients revealed three additional positions that correlated with NRTI: 65 (0/269 versus 25/941; uncorrected P ¼ 0.01), 221 (0/269 versus 29/941; uncorrected P ¼ 0.007), and 223 (0/269 versus 28/ 941; uncorrected P ¼ 0.008). Of these positions, position 65 is a known drug resistance mutation, whereas positions 221 and 223 are novel. The previously reported NRTI resistance mutation, Y115F, occurred more commonly in treated than in untreated individuals in the total set of patients with a P ¼ 0.05, but this P value was not statistically significant following the adjustment for multiple comparisons. Median number of differences from consensus B (mutations, grey bars) and known drug resistance mutations (black bars) according to the number of NRTI received. The patients receiving three to four and five or more NRTI were more likely to have also received NNRTI. The median number of NRTI mutations for these two groups was four and six, respectively. The median number of NNRTI mutations for both groups was one. Fig. 2 . Mutation frequency at RT positions 1-240 according to the number of NRTI received in NNRTI-naive patients (with the exception of positions 65, 221, and 223, which include data from all patients). Each bar represents one of the subgroups as defined in Fig. 1, namely 0, 1-2, 3-4 , and 5+ NRTI. At each position, a chi-square test of independence was performed to determine if there was an association between NRTI treatment and a mutation at the given position. Positions that were significantly associated with therapy using an FDR of 0.01 (chi-square analysis) are boxed with a solid line; those that were significant using an FDR of 0.05 are boxed with a dotted line. Positions that were significantly associated with increasing drug therapy (logistic regression) using an FDR of 0.01 are marked with two arrows; those that were significant using an FDR of 0.05 are marked with one arrow.
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Correlations between NRTI resistance mutations
To identify patterns of drug resistance mutations, we calculated the pairwise binary (phi) correlation coefficients among the 18 previously reported NRTI resistance mutations and the additional nine NRTIassociated mutations that we discovered in this study. Correlations between NNRTI resistance mutations We repeated the above analysis on the 11 NNRTIassociated mutations that we determined to be statistically significant in this study. 
Discussion
The number of RT mutations between positions 1 and 240 in subtype B virus increased from a median of four in untreated individuals to 14 in heavily treated individuals. The increase in mutations with treatment is largely explained by the 18 known NRTI-associated mutations and the 14 known NNRTI-associated mutations. However, mutations at nine additional positions (20, 39, 43, 203, 208, 218, 221, 223, 228 ) that were for the most part conserved in untreated persons were also strongly associated with drug therapy. Mutations at 11 additional positions were weakly associated with therapy. Sixty-eight positions were polymorphic and appeared to be neutral. One hundred and twenty positions were invariant.
The nine previously unreported mutations included K20R, T39A, K43E/Q/N, E203D/K, H208Y, D218E, H221Y, D223E/Q, L228H/R. Seven of these mutations were clearly associated with NRTI therapy alone; two (H221Y and D223E/Q) were associated with therapy only if individuals receiving both NRTI and NNRTI were included. Each of the nine new mutations was highly correlated with the number of previously received NRTI and generally occurred together with other known NRTI-associated mutations.
The fact that the newly identified mutations occur primarily in combination with previously reported drug resistance mutations suggests that they act as accessories, increasing the level of resistance to NRTI or compensating for decreases in replication associated with other mutations. This supposition should be tested experimentally by site-directed mutagenesis studies to assess the effect of these mutations on drug susceptibility and replication in a wild-type construct and a construct containing the NRTI resistance mutations with which the new mutation commonly occurs.
Copyright © Lippincott Williams & Wilkins. Unauthorized reproduction of this article is prohibited. with NRTI therapy or found to be associated in this study. The graph is a two-dimensional projection of the distances among the 27 positions, where the similarity between any two positions is measured by their binary (phi) correlation coefficient among patients who have received three or more NRTI. Positions that are close together on the graph are those with a high degree of comutation in patients, whereas positions that are far apart are those with a low or negative degree of co-mutation.
We performed a cross-sectional analysis of RT mutations in isolates from persons treated with a range of RT inhibitor therapy. Such data indicate the prevalence of specific mutations in individuals with varying degrees of RT inhibitor experience. Only 75 sequences were available from individuals receiving a single NRTI, predominantly zidovudine or didanosine. Longitudinal data would indicate the incidence of new mutations in patients receiving new RT inhibitors and would provide additional insight into the role played by individual mutations in the development of resistance to specific drugs.
One of the nine previously unreported mutations, H208Y, has been associated with foscarnet resistance [11] , but none of the other mutations have previously been associated with antiretroviral therapy. The mutations at positions 39 and 43 are close to the thymidine analog-associated mutation at position 41 and are correlated with this mutation. The mutations at positions 218, 221, 223, and 228 are in a highly conserved part of the RT gene that is close to the known NRTIassociated mutations at positions 215 and 219. These amino acids make up parts of the conserved motifs D and E found in all retroviruses [12] .
Although the associations between drug therapy and mutations at 221 and 223 were only significant when NNRTI-treated as well as NRTI-treated patients were analyzed, we suspect that these are primarily NRTIassociated mutations because these mutations also occurred in the absence of NNRTI therapy. To explore this question further, we examined the atomic coordinates of these residues within the three-dimensional structure of HIV-1 RT co-crystallized with the NNRTI nevirapine [13] . The closest molecular distances between atoms in H221 and D223 to nevirapine were 11 and 9.5 Å , respectively whereas the closest molecular distances between the 14 known NNRTIassociated positions and nevirapine is between 2.6-8.8 Å [13] .
The correlation and principal components analysis revealed several mutational clusters. The distinction between the multi-nucleoside resistance mutations [14, 15] and the thymidine analog mutations defined the first principal component. The distinction between the two sets of thymidine analog mutations defined the second principal component. The strong association between multi-nucleoside resistance and mutations at positions 65 and 115 has not been previously reported. The fact that the thymidine analog associated mutations often cluster into two groups has been noted by others [16] [17] [18] and may be particularly relevant for resistance to the nucleotide RT inhibitor tenofovir in that mutations at positions 41, 210, and 215 are associated with higher levels of resistance to tenofovir than mutations at positions 67, 70, and 219 [19] . The fact that M184V was not statistically associated with any other mutation suggests that the decreased fitness associated with this mutation [20, 21] does not consistently lead to the development of any other treatmentassociated mutation.
Several interactions between NNRTI resistance mutations and NRTI resistance mutations have been reported. The NNRTI mutations at positions 100 and 181 have been shown to reverse T215Y-mediated zidovudine resistance mutations [22, 23] . Mutations at positions 74 and 75 have been reported to develop following the development of a mutation at position 190 in isolates cultured in the presence of an experimental NNRTI compound [24] . We did not observe a negative association between mutations at positions 181 and 215. However, we did observe a positive correlation between mutations at positions 74 and 190.
The large number of mutations associated with NRTI therapy is probably a consequence of the high genetic barrier to resistance posed by most dual NRTI combinations. In patients receiving a dual NRTI combination, it is generally not sufficient for HIV-1 to develop just one or two RT inhibitor resistance mutations to escape virus suppression; rather multiple primary as well as secondary accessory mutations appear to be required. The intricate patterns of mutational clusters are further evidence of this genetic barrier to resistance. The negative interactions between certain mutations suggest that resistance does not result simply from the accumulation of any RT mutations but rather from specific combinations of mutations.
